← Eichor
Condition: Her2 Positive Early Stage Breast Cancer Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Her2 Positive Early Stage Breast Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2-
Phase 3 · 1 location(s) · Genentech, Inc. · NCT07541079Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer
Phase 2 · 1 location(s) · Hebei Medical University Fourth Hospital · NCT07492394NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline
Phase 2 · 8 location(s) · Swiss Cancer Institute · NCT06452394Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Recep
Phase 2 · 9 location(s) · Jonsson Comprehensive Cancer Center · NCT04553770A Phase II Clinical Study of Treatment With Disitamb Vedotin Plus Pyrotinib in HER2-positive Early Breast Cancer
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT06001086JUdicious Surveillance for Trastuzumab Induced Cardiotoxicity in the First Year
NA · 1 location(s) · Women's College Hospital · NCT06930521A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuz
Phase 3 · 1 location(s) · Fudan University · NCT06992882Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer
Phase 2 · 7 location(s) · Rutgers, The State University of New Jersey · NCT07402473Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted Therapy
Phase 3 · 1 location(s) · Fudan University · NCT07528716Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Phase 3 · 229 location(s) · Novartis Pharmaceuticals · NCT05827081Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Subop
Phase 2 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT07340398Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer
Phase N/A · 1 location(s) · Institute of Oncology Ljubljana · NCT06650423Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
Phase 2 · 1 location(s) · Fudan University · NCT05582499RADIANT: Pre-op Radiation With Abemaciclib and Letrozole
Phase 1 · 4 location(s) · Mridula George, MD · NCT06139107A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05035836Pyrotinib in Women With High-risk in Early Stage Breast Cancer
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT05834764A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth
Phase 2 · 78 location(s) · Eli Lilly and Company · NCT07287098A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Phase 3 · 317 location(s) · Merck Sharp & Dohme LLC · NCT06966700Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stag
Phase 2 · 17 location(s) · Merck Sharp & Dohme LLC · NCT06797635Active Surveillance in Older Women With ER+ Breast Cancer
Phase N/A · 1 location(s) · University of Pittsburgh · NCT07262138Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-S
NA · 4 location(s) · Emory University · NCT06534125Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
Phase 2 · 2 location(s) · Baylor Breast Care Center · NCT05020860I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Phase 2 · 42 location(s) · QuantumLeap Healthcare Collaborative · NCT01042379Efficacy and Safety of Culmerciclib Plus Aromatase Inhibitors in a Response-Adapted Neoadjuvant Strategy for Highly Prol
Phase 2 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT07616453ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer
Phase 2 · 1 location(s) · Peking University People's Hospital · NCT06970912NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer.
Phase N/A · 1 location(s) · Henan Cancer Hospital · NCT06781281Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer
Phase 2 · 1 location(s) · Peking University · NCT04481932Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC
Phase 2 · 1 location(s) · Shanghai Jiao Tong University School of Medicine · NCT06500208Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT07407920Evaluation of HER2DX Assay on Treatment Decisions in Patients With Early Stage HER2+ Breast Cancer: the HER2BREASTDX
Phase N/A · 1 location(s) · European Institute of Oncology · NCT06723990
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.